Aim Immunotech INC 8-K filings

AIM ImmunoTech announced that NYSE American has accepted its plan to regain compliance with minimum stockholders' equity requirements.

AIM ImmunoTech announces the appointment of David Chemerow as an Independent Director to its Board, effective February 24, 2025.

AIM ImmunoTech reports that the Erasmus Medical Center Safety Committee approved the Phase 2 study of Ampligen and AstraZeneca's Imfinzi as a potential combination treatment for late-stage pancreatic cancer.

AIM ImmunoTech Inc. has announced it will delay its planned offering until after the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenza outbreaks.

AIM ImmunoTech announces Safety Committee approval to advance its Phase 2 clinical trial combining Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment.

AIM ImmunoTech's CEO and another executive voluntarily forgo their 2024 cash bonuses to focus financial resources on Ampligen R&D.

AIM ImmunoTech's 2024 Annual Meeting saw the election of four directors, ratification of the auditor, and rejection of executive compensation.

AIM ImmunoTech has received a warning from the NYSE American regarding non-compliance with minimum stockholders' equity requirements, placing its listing at risk.

AIM ImmunoTech announces a cash conservation plan where independent board members will receive 100% of their compensation in company stock, aligning with previous executive pay reductions.

AIM ImmunoTech has entered into a securities purchase agreement to raise approximately $1.26 million through a registered direct offering and concurrent private placement.

AIM ImmunoTech has revised its CEO's compensation, reducing his cash salary and issuing restricted stock, while also correcting the effective dates of previous compensation changes for both the CEO and COO.

AIM ImmunoTech has adopted amended bylaws to address issues raised by a Delaware Supreme Court ruling regarding advance notice provisions for stockholder nominations and proposals.

The Delaware Supreme Court partially reversed a lower court ruling regarding AIM ImmunoTech's bylaws, but the 2023 director election results remain unchanged.

AIM ImmunoTech has announced a $2 million capital raise through a registered direct offering and concurrent private placement of common stock and warrants.

AIM ImmunoTech has entered into a Note Purchase Agreement, securing $2.5 million through a private placement with Streeterville Capital, LLC.

AIM ImmunoTech reports positive topline results from a Phase 2 study of Ampligen, showing potential to reduce fatigue in individuals with Post-COVID conditions.

AIM ImmunoTech has released supplemental data for its Pancreatic Cancer Early Access Program for Q1 2024.